Category Archives: ALS Treatment

NIH researchers discovered a new form of ALS that begins in childhood. The study linked the disease to a gene called SPLTC1. As part of the study, NIH senior scientist Carsten Bonnemann, M.D., (right) examined Claudia Digregorio (left), a patient from the Apulia region of Italy. Continue reading →

-Featuring Stanley H. Appel, M.D., internationally renowned researcher and neurologist--Webinar to be held Friday, June 11, 2021 at 11:30 a.m. ET- HOUSTON, June 02, 2021 (GLOBE NEWSWIRE) -- Coya Therapeutics, Inc., (Coya), a clinical-stage biotechnology company developing first-in-class approaches utilizing autologous regulatory T cells (Tregs) and Treg-derived exosome therapeutics for neurodegenerative and autoimmune diseases, today announced that it will host a key opinion leader (KOL) webinar on ALS001, the Companys lead asset for the treatment of amyotrophic lateral sclerosis (ALS), on Friday, June 11, 2021 at 11:30 a.m. Continue reading →

By sequencing the genomes of 11 individuals with a severe form of childhood amyotrophic lateral sclerosis (ALS), a team led by National Institutes of Health researchers has identified a set of rare mutations that cause the disease. In these patients, they discovered variants in the gene SPTLC1, which is involved in lipid metabolism, and found that these mutations disrupt the production of an enzyme called serine palmitoyltransferase (SPT), leading to unrestrained sphingolipid production and accumulation in the motor neurons affected in ALS. Continue reading →

The Frisbee traveled about 30 feet before landing on the dirt pathway. Continue reading →

VANCOUVER, British Columbia--(BUSINESS WIRE)--Alpha Cognition Inc. (TSX-V: ACOG) (Alpha Cognition or the Company), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, is pleased to announce that it will host its first annual Virtual R&D Day for analysts and investors on Tuesday, June 22, 2021, from 1:00PM to 3:00PM EDT Continue reading →

Ahead of this years Rare Disease Week on Capitol Hill, held virtually July 1422, the EveryLife Foundation will award grants to top advocates of rare disease organizations who participate in the weeks pre-events. The top 50 point-earners will be eligible to win $1,000 to $5,000 in grants, totaling up to $100,000, the foundation announced in a release. The pre-event Meet and Greet Session, to be held June 8 and 9, brings together regional and state-wide rare disease advocates to interact in virtual games and prize sessions Continue reading →

Spearheaded by the legendary Yankee Hall Of Famer Lou Gehrig, This Wednesday June 2nd, And from now on every June 2nd, Major League Baseball will honor Lou Gehrig for not only his legacy on the field but to raise awareness and funds for the disease that ended Lou's life at the young age of 37. ALS is Amyotrophic Lateral Sclerosis, a vicious disease that attack nerve cells in the brain and spinal cord. Those affected lose their ability to walk, talk and eventually breathe Continue reading →

Jan. 26, 2021 12:00 UTC Funding Supports Aclipse Therapeutics and Sheffield Institute of Translational Neurosciences Development of M102 in Amyotrophic Lateral Sclerosis RADNOR, Pa.--(BUSINESS WIRE)-- Aclipse Therapeutics (Aclipse or the Company), a private biopharmaceutical company, today announced that the Company and its collaborator, The Sheffield Institute for Translational Neuroscience (SITraN) at the University of Sheffield in the United Kingdom (UK), were awarded a drug development research grant of 1.6 million (approximately US $2.2 million) from the UKs Medical Research Council (MRC), one of the largest funders of medical research worldwide, to support the translational development of M102. Continue reading →

Greg Gowe at the Vancouver airport, on his way to a clinical trial appointment in Montreal in November 2020. Continue reading →

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 2020 by Company, Regions, Type and Application, Forecast to 2025 released by MarketQuest.biz is a specialized and in-depth study of the market with a detailed focus on the global market trend analysis. The report aims to provide an overview of the global Amyotrophic Lateral Sclerosis (ALS) Treatment market with detailed market segmentation by component, deployment, organization size, the end-user. The market is scrutinized in terms of market size, market share, status, trends, competitive scenario, and potential growth opportunities with a forecast till 2025 Continue reading →